🇺🇸 FDA
Pipeline program

Esketamine-lidocaine group

2023-451-2

Unknown small_molecule active

Quick answer

Esketamine-lidocaine group for Postoperative Chronic Pain is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Postoperative Chronic Pain
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials